Mineralys Therapeutics

Pharma

ICER says AZ's Baxfendy doesn't clear its cost-effectiveness bar

AZ’s newly approved blood pressure drug Baxfendy does not clear the bar for effectiveness relative to its price, says U.S. drug price watchdog ICER.

Kevin Dunleavy Aug 13, 2026 11:37am

AZ nets key hypertension nod for Baxfendy, plus new Fasenra use

May 18, 2026 11:23am